BTIG Maintains Buy on Rapport Therapeutics, Raises Price Target to $89
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
BTIG analyst Kambiz Yazdi maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $75 to $89.
BTIG analyst Kambiz Yazdi maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $75 to $89.